Jeffrey Herron

Associate Professor

University of Washington
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Year:

2026

Adaptive neuromodulation systems and implantable brain-computer interfaces have made notable strides in recent years, translating experimental prototypes into clinical applications and garnering substantial attention from the public. This surge in interest is accompanied by increased scrutiny related to the safety, efficacy, and ethical implications of these systems, all of which must be directly addressed as we introduce new neurotechnologies. In response, we have synthesized the insights resulting from discussions between groups of experts in the field and summarized them into five key domains essential to therapeutic device development: (1) analyzing current landscape of neuromodulation devices and translational platforms (2) identifying clinical need, (3) understanding neural mechanisms, (4) designing viable technologies, and (5) addressing ethical concerns. The role of translational research platforms that allow rapid, iterative testing of hypotheses in both preclinical and clinical settings is emphasized. These platforms must balance experimental flexibility with patient safety and clear clinical benefit. Furthermore, requirements for interoperability, modularity, and wireless communication protocols are explored to support long-term usability and scalability. The current regulatory processes and funding models are examined alongside the ethical responsibilities of researchers and device manufacturers. Special attention is given to the role of patients as active contributors to research and to the long-term obligations we have to them as the primary burden-bearers of the implanted neurotechnologies. This article represents a synthesis of scientific, engineering, and clinical viewpoints to inform key stakeholders in the neuromodulation and brain-computer interface spaces.

Year:

2025

Year:

2025

Deep brain stimulation (DBS) of the ventral capsule and ventral striatum (VC/VS) is an effective therapy for treatment-resistant obsessive–compulsive disorder (trOCD). DBS initiation often produces acute improvements in mood and energy. These acute behavioral changes, which we refer to as “approach behaviors,” include increased social engagement and talkativeness. We investigated the relationship between stimulation amplitude, spectral power in the ventrolateral prefrontal cortex (vlPFC), and speech rate in one male patient with trOCD implanted with bilateral VC/VS DBS leads and subdural electrodes adjacent to the orbitofrontal cortex and vlPFC. Several times over the first 24 weeks of therapy, we conducted experiments where we recorded data during epochs of high-amplitude or zero-/low-amplitude stimulation. We found that both the speech rate and vlPFC power in a high beta frequency band (31 ± 1.5 Hz, 1/ f activity removed) increased during high-amplitude as compared with low-amplitude periods. The speech rate correlated with vlPFC high beta power. These effects were more consistent across time points in the left hemisphere than the right. At Week 24, we performed an experiment where stimulation was held constant, while the patient was asked to speak or remain silent. We showed that the presence or absence of speech was not sufficient to increase the vlPFC high beta power, suggesting stimulation is a key driver of the observed neurobehavioral phenomenon. Our results suggest vlPFC high beta power is a biomarker for approach behaviors associated with VC/VS DBS.

Year:

2025

Introduction Recording-enabled deep brain stimulation devices are used to treat individuals with a variety of neurological disorders, but current systems are only able to connect to a maximum of two brain leads. Off-label implantation of additional leads for unique clinical research questions requires bilateral implantable pulse generators (IPGs), however, slight mismatches in clock rates across IPGs produce mismatched stimulation frequencies. This mismatch creates high amplitude beat frequency artifacts (BFA) that occur at regular intervals and contaminate underlying neural signals, presenting unique challenges for future adaptive DBS (aDBS) algorithm development utilizing dual IPGs. Method We quantified BFA intervals in local field potential (LFP) recordings from 26 patients implanted with two IPGs during both continuous (cDBS; n=21) and adaptive (aDBS; n=5) stimulation modes. Results BFAs occur in all patients at varying intervals and require both devices to be turned on. We found that BFAs result from mismatched stimulation frequencies, where smaller frequency differences result in longer intervals between BFAs. The range in interval length between artifacts was 112 seconds to 30 minutes across patients. Switching to adaptive DBS (aDBS) decreased this interval to 30 seconds in a single patient. Conclusion In a dual-device scenario, BFAs should be considered in LFP analysis or future aDBS algorithm design through implementation of mitigation strategies such as onset times and selection of minimally affected recording channels.

Year:

2025

Objective The development of increasingly complex implantable neuromodulation devices requires extensive benchtop validation and testing prior to in vivo implementation. Our goal is to enable this in vitro testing by creating a benchtop system that is accessible, easy-to-use, and functions reliably across academic and industry environments, reducing discordant results that arise from discordant approaches. Furthermore, such a system paves the way for standardizing benchtop characterization of future implantable systems by establishing a repeatable and comparable methodology for validating these devices and their capabilities. Approach We describe the NeuroTest Board (NTB), a low-cost, open-source device that combines a low-noise current source waveform generator with a high-precision data acquisition system. We provide information on its architecture, operation, and performance as an initial benchmark of the potential capabilities of the system. Main results We demonstrate the use of the NTB to assess electrophysiology systems in two separate applications. In one case, we assess a commonly used laboratory system (the RHD2132 headstage and Open Ephys data acquisition system), while the second case characterizes an investigational neuromodulation device in development for human use (the CorTec Brain InterChange). Following this initial sensing characterization, we explore stimulation-related artifacts that would hamper in vivo data collection. With the NTB, we develop and evaluate artifact mitigation strategies for each system, thus demonstrating an example application of this benchtop testbed. Significance The ability to test neuromodulation devices against a common benchmark will enable faster development of novel therapeutics by increasing inter-institutional reliability and decreasing troubleshooting time.

Year:

2025

Year:

2024

Deep brain stimulation (DBS) has garnered widespread use as an effective treatment for advanced Parkinson’s Disease (PD). Conventional DBS (cDBS) provides electrical stimulation to the basal ganglia at fixed amplitude and frequency, yet patients’ therapeutic needs are often dynamic with residual symptom fluctuations or side-effects. Adaptive DBS (aDBS) is an emerging technology that modulates stimulation with respect to real-time clinical, physiological, or behavioral states, enabling therapy to dynamically align with patient-specific symptoms. Here, we report a novel aDBS algorithm intended to mitigate movement slowness by delivering targeted stimulation increases during movement using decoded motor signals from the brain. Compared to cDBS and a control algorithm that decreases stimulation during movement, our approach demonstrates enhanced clinical efficacy, with improvements in movement speed, reduced dyskinesia, and better patient-reported therapeutic quality. Furthermore, we demonstrate proof-of-principle of a machine learning pipeline capable of remotely optimizing aDBS parameters in a home setting. This work illustrates the potential of movement-responsive aDBS as a new therapeutic approach and highlights how machine learning assisted programming can simplify optimization to facilitate translational scalability.

Year:

2024

Year:

2023

Year:

2022

Year:

2020

Collaborators (20)

Alik Widge

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Garrett Banks

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Sameer Sheth

Baylor College of Medicine

UNITED STATES
View details

Eric Storch

Professor and Vice Chair

Baylor College of Medicine

UNITED STATES
View details

Rosana Esteller

Professor

University of Minnesota

UNITED STATES
View details

Theoden Netoff

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Maryam Shanechi

Sawchuk Endowed Chair and Professor

University of Southern California

UNITED STATES
View details

Jessica Bowersock

Lecturer

University of Arizona

UNITED STATES
View details

Simon Little

Assistant Professor Neurology

University of California, San Francisco

UNITED STATES
View details

Joseph West

Associate Professor

University of Melbourne

AUSTRALIA
View details

Nora Vanegas Arroyave

Associate Professor of Neurology

Baylor College of Medicine

UNITED STATES
View details

Nathan Staff

Mayo Clinic

UNITED STATES
View details

Timothy Denison

Professor of Neurotechnology and Royal Academy of Engineering Chair in Emerging Technologies

University of Oxford

UNITED KINGDOM
View details

Joseph Neimat

University of Louisville

UNITED STATES
View details

Jack Gallant

Professor

University of California, Berkeley

UNITED STATES
View details

Wolf-Julian Neumann

Head of AI Innovation and Therapeutic Neurotechnology

Charité - Universitätsmedizin Berlin

GERMANY
View details

Kristin Sellers

Associate Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Gregory Worrell

Professor

Mayo Clinic Minnesota

UNITED STATES
View details

Kyle Mitchell

Associate Professor

Duke University School of Medicine

UNITED STATES
View details

Kristin Kostick

Senior Staff Scientist

Baylor College of Medicine

UNITED STATES
View details